NCT05143229View on ClinicalTrials.gov

Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 28, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Breast Cancer
Interventions
DRUG

Alpelisib

PI3K inhibitor

DRUG

Sacituzumab govitecan

Trop-2-directed antibody and topoisomerase inhibitor drug conjugate

Trial Locations (7)

64064

The University of Kansas Cancer Center - Lee's Summit, Lee's Summit

64116

The University of Kansas Cancer Center - North Kansas City Hospital, Kansas City

64154

The University of Kansas Cancer Center - North, Kansas City

66205

The University of Kansas Clinical Research Center, Fairway

The University of Kansas Cancer Center, Westwood

66210

The University of Kansas Cancer Center - Overland Park, Overland Park

66211

The University of Kansas Cancer Center - Indian Creek, Overland Park

Sponsors
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

collaborator

Gilead Sciences

INDUSTRY

lead

University of Kansas Medical Center

OTHER